Biomarkers of Antidepressant Treatment in Adolescents With Major Depression (The Adolescents MDD Study)

NCT ID: NCT01185977

Last Updated: 2014-07-03

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 26 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-04-30

Brief Summary

This study will aim to evaluate the use of Electroencephalography (EEG) biomarkers in adolescent depression. Two specific hypotheses will be tested:

H1: Early decreases in prefrontal cordance values will be greater in responders to antidepressant therapy than in medication non-responders.

H2: Subjects with high Antidepressant Treatment Response(ATR) Index values [i.e., predicted to show symptomatic improvement with fluoxetine (FLX)] will achieve greater improvement in symptoms and in functional status than those with low ATR values.

Exploratory analyses will be undertaken to compare and contrast the cordance changes and ATR values in medication and placebo-treated responders and non-responders.

Detailed Description

A total of 26 adolescent subjects with Major Depressive Disorder(MDD), ages 12 to 20, will be consented and join this project at UCLA. For analytic purposes, we will define an "enrolled" subject as one who has completed the single-blind lead-in week and one week of double-blind treatment, and the three EEG recordings at these visits, as any subject who leaves the project prior to that point cannot contribute useful data to testing our hypotheses.

Subjects who enroll in this project will receive 1 week of single-blind placebo lead-in, followed by 8 weeks of double-blind randomized treatment either with fluoxetine (FLX), a Selective Serotonin Reuptake Inhibitor (SSRI) with FDA approval for use in this age group, or with placebo. Brain activity will be assessed with Qualitative EEG (QEEG) recording at pretreatment baseline, after lead-in, and at 1, 2, 4, and 8 weeks of treatment to expand the evidence base on the neurophysiology of treatment response in adolescents. Subjects will be assessed for symptom change, adverse events, and suicidality at each visit. Functional measures related to treatment will be assessed at baseline and at weeks 4 and 8. Subjects and the staff who interact with them will be blinded to QEEG biomarker values during the project.

Conditions

Major Depressive Disorder

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Fluoxetine

1 week single-blinded placebo lead-in and double-blinded FLX treatment for 8 weeks

Group Type: ACTIVE_COMPARATOR

Fluoxetine

Intervention Type: DRUG

one-week single-blind PBO-lead-in phase, FLX 10 mg/d for 4 days then 20 mg/d of FLX thereafter

Placebo (PBO)

Placebo treatment for 9 weeks of study

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

One pill of PBO for 4 days then two pills of PBO thereafter

Interventions

Fluoxetine

one-week single-blind PBO-lead-in phase, FLX 10 mg/d for 4 days then 20 mg/d of FLX thereafter

Intervention Type: DRUG

Placebo

One pill of PBO for 4 days then two pills of PBO thereafter

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Outpatients with non-psychotic, unipolar Major Depressive Disorder (MDD) based on the K-SADS-PL
• A score of ≥ 45 on the Children's Depression Rating Scale-Revised (same threshold as TADS). As with the TADS trial, depressed mood must have been present in at least 2 of 3 contexts (home, school, among peers) for at least 6 weeks prior to consent.
• Age range: 14-18.
• Patients with suicidal ideation are eligible only if the thoughts of death or of life not being worth living are not accompanied by a plan or intention for self-harm.

Exclusion Criteria

• Subjects will have no unstable medical illness that would prevent completion of participation in the trial (determined as needed from physical examination, ECG, laboratory safety tests, as well as a review of systems). Other specific exclusionary criteria also are based on the BRITE-MD parameters, and include:

1. mentally or legally incapacitated, unable to give informed consent;

2. meets DSM-IV criteria for anorexia nervosa, bulimia nervosa, obsessive-compulsive disorder, any cognitive disorder, bipolar disorder, psychotic disorder, or major depression with psychotic features;

3. MMSE (Folstein et al., 1975) score ≤ 24;

4. evidence of drug dependency or substance abuse within the preceding nine months;

5. stable and in remission on current psychotropic medication(s);

6. any ECT within the past six months;

7. failure to tolerate FLX or treatment failure with an adequate trial of FLX in the current episode;

8. FLX would be contraindicated (e.g., hyponatremia with a prior SSRI);

9. treatment with an MAOI within the past four weeks;

10. any medical illness severe enough to significantly affect brain function or to interfere with interpretation of study results;

11. history of seizures, brain surgery, skull fracture, significant head trauma, or abnormal EEG;

12. psychiatric hospitalization indicated (e.g., imminent danger to self or others);

13. initial QEEG recording is contaminated with artifact so that determination of the biomarker is precluded;

14. use of medications known to affect brain function (e.g., antidepressants, anticonvulsants/mood stabilizers, anticholinergics, antipsychotics, benzodiazepines - same list as in BRITE-MD). Based on the TADS trial, we will also exclude for concurrent diagnoses of attention-deficit hyperactivity disorder managed with psychostimulants, pervasive developmental disorder, and mental retardation (mild, moderate, severe, or profound);

15. subject is currently pregnant, or is of child-bearing potential and not using a medically acceptable means of birth control (defined as oral contraceptive pill or implant, condom, diaphragm, spermicide, IUD, s/p tubal ligation, partner with vasectomy).

• Minimum Eligible Age: 14 Years
• Maximum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University of California, Los Angeles

OTHER

Sponsor Role: lead

Responsible Party

Ian A. Cook, M.D.

Principal Investigator

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Ian A Cook, MD

Role: PRINCIPAL_INVESTIGATOR

Universityof California Los Angeles

Locations

UCLA Semel Institute

Los Angeles, California, United States

Countries

United States

Related Links

http://www.DepressionLA.com

Related Info

Other Identifiers

090713201

Identifier Type: -

Identifier Source: org_study_id